08/19/2015 16h02

Greiner Bio-One announces R$ 42 million investment in Americana after being assisted by Investe SP

Investment plan will be conducted in two phases; the first will start in August

Investe São Paulo
  • Download Plínio Moraes Junior

    In addition to the expansion works, Greiner Bio-One will invest in the production increase, seeking efficiency, productivity gains, technology and adequate workforce

  • Download Plínio Moraes Junior

    “The State of São Paulo is the most logical destination for this type of investment. The universities that teach the best professionals in the country are here”, said Quirós

  • Download Plínio Moraes Junior

    The mayor of Americana highlighted the importance of the company to believe in the potential of Brazil and in the city’s population, despite the country’s current scenario

  • Download Plínio Moraes Junior

    The general manager of the company in Brazil, Haroldo Fontes Graci, highlighted the local commitment of the company, recalling the moment when the plant was built

Greiner Bio-One, a technology company from Austria, which operates in the healthcare industry in the segments of bioscience, diagnostics and is a global co-leader in preanalytics, will start in August the expansion of its plant in Americana. The plant, located in the state of São Paulo, is the only one in Latin America.

The investment of R$ 42 million in industrial expansion and machinery will take place in two phases. The first phase begins in the second half of this year with the construction of the new facilities that will be completed by the end of 2016. The beginning of its activities are planned for January 2017.

With this expansion, the company will double its current production capacity and its growth potential will reach approximately 800 million vacuum blood collection tubes manufactured per year. Greiner Bio-One is planning to become a leader in the Brazilian market.

On August 11, the CEO of Greiner Bio-One, Rainer Perneker, will be present at the cornerstone ceremony, in Americana, symbolizing the beginning of the expansion works, presenting the company’s business strategy, which is part of one of the group’s plan called “Vision 2020”. Created in 2012, based on a policy on sustainable development, it defines the scope, decision, construction, implementation and monitoring of the company’s projects within a period of eight years.

In addition to the expansion works, the company will invest in production increase, according to the demand, with efficiency, productivity gains, technology and adequate workforce. “Our vision is not limited to indicators. This investment is strong, substantial and proves a commitment to the country. Since 2003, when Greiner Bio-One began its activities in Brazil, we believed in the growth of this market,” said Perneker.

Following the clearly defined objectives set out in “Vision 2020”, the General Manager of Greiner Bio-One Brazil, Haroldo Fontes Graci said that the investment will stimulate the development of the national industrial park. “By investing in Brazil, we develop local suppliers, which will benefit the new industries in the segment wishing to invest in the country,” he says.


Potential

The project relies on the support from Investe São Paulo, the State Government investment and competitiveness promotion agency associated with the Department of Economic Development, Science, Technology and Innovation. The president of Investe São Paulo, Juan Quirós, said that the market for supplies/equipment of the health industry has a huge growth potential in Brazil, since this segment currently relies on imported products.

“The State of São Paulo is the most logical destination for this type of investment. The universities that teach the best professionals in the country are here. In addition, the logistics infrastructure and the complex supply chain of the industry causes an increasing number of companies that operate in the healthcare industry to settle here,” he said. Quirós also noted that the segment is considered a priority at Investe São Paulo.


Greiner Bio-One

Greiner Bio-One is a technology company in the healthcare industry that operates in the segments: pre-analytics, life science and diagnostics. Reference in innovation, from development to manufacturing, its portfolio of products meets all national and international safety standards, with the most rigorous quality standards.

In addition to Brazil, the production sites in Austria, Germany, USA, Hungary and Thailand make up Greiner Bio-One International AG, which together generate a turnover of 388 million euros. The group has more than 1,800 employees operating globally in 24 subsidiaries and numerous distributors in more than 100 countries.

The headquarters in Austria Greiner Bio-One GmbH is a technology partner of universities, research institutes and the diagnostics, pharmaceutical and biotechnology industries.